CEO and President of Blueprint Medicines Corp (30-Year Financial, Insider Trades) Jeffrey W. Albers (insider trades) sold 20,000 shares of BPMC on 08/19/2020 at an average price of $75.02 a share. The total sale was $1.5 million.
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. Its drug candidates include avapritinib, BLU 554, BLU-782 and BLU-667. Blueprint Medicines Corp has a market cap of $4.11 billion; its shares were traded at around $74.37 with and P/S ratio of 49.41. GuruFocus has detected 2 severe warning signs with Blueprint Medicines Corp. .
CEO Recent Trades:
- CEO and President Jeffrey W. Albers sold 20,000 shares of BPMC stock on 08/19/2020 at the average price of $75.02. The price of the stock has decreased by 0.87% since.
Directors and Officers Recent Trades:
- Principal Accounting Officer Ariel Hurley sold 700 shares of BPMC stock on 08/17/2020 at the average price of $75. The price of the stock has decreased by 0.84% since.
For the complete insider trading history of BPMC, click here
.
